Summary
VAL closed Friday lower at €153.76, a decrease of 0.09% from Thursday's close, completing a monthly increase of 3.89% or €5.76. Over the past 12 months, VAL stock gained 19.45%.
VAL is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XETRA (EUR).
Want to track VAL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
VAL Chart
Amundi MSCI EMU Value Factor Index Fund Dividends
| VAL VAL 12 Dec 2023 | Other | €4.63 Per Share |
| VAL VAL 7 Dec 2022 | Other | €1.12 Per Share |
| VAL VAL 6 Jul 2022 | Other | €3.89 Per Share |
| VAL VAL 8 Dec 2021 | Other | €0.78 Per Share |
| VAL VAL 7 Jul 2021 | Other | €2.56 Per Share |
Amundi MSCI EMU Value Factor Index Fund Earnings
VAL have yet to publish their earning reports.
| VAL VAL 12 Dec 2023 | Other | €4.63 Per Share |
| VAL VAL 7 Dec 2022 | Other | €1.12 Per Share |
| VAL VAL 6 Jul 2022 | Other | €3.89 Per Share |
| VAL VAL 8 Dec 2021 | Other | €0.78 Per Share |
| VAL VAL 7 Jul 2021 | Other | €2.56 Per Share |
VAL have yet to publish their earning reports.
Amundi MSCI EMU Value Factor Index Fund (VAL) FAQ
What is the stock price today?
The current price is €153.76.
On which exchange is it traded?
Amundi MSCI EMU Value Factor Index Fund is listed on XETRA.
What is its stock symbol?
The ticker symbol is VAL.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Amundi MSCI EMU Value Factor Index Fund ever had a stock split?
No, there has never been a stock split.
Amundi MSCI EMU Value Factor Index Fund Profile
| XPAR Exchange | United Kingdom Country |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
Contact Information
Address: Stonebridge House
Phone: 44 24 7679 6496
Website: https://www.valirx.com
2025 © Marketlog. All Rights Reserved.
